AnaptysBio, Inc.
NASDAQ:ANABBiotechnology
-$1.07 today
- Market cap
- $1.40B
- Beta
- 0.41
- P/E (TTM)
- -59.7
- EPS (TTM)
- -$0.93
Volume 0.57M
Average 0.76M
ANAB Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
AnaptysBio, Inc.NASDAQ: ANAB
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables dips below year-ago levels
Q1 FY2026 accounts receivables of $8.1M fell 64.6% year over year, behind the +44.2% change in trailing-twelve-month accounts receivables. Sequentially, it fell 80.6% from the prior quarter.
Context
- Accounts receivables amounted to 2.9% of revenue in FY2025, down 34.2 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -64.6% toward the trailing-twelve-month pace of +44.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 6.92M USD
- Year-over-year change
- +120.4%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.92M | +120.4% |
| FY2024 | 2024-12-31 | (33.91M) | -524.3% |
| FY2023 | 2023-12-31 | (5.43M) | -900.4% |
| FY2022 | 2022-12-31 | (543K) | +38.0% |
| FY2021 | 2021-12-31 | (876K) | — |
Accounts Receivables vs competitors
How ANAB compares with its peers on the latest reported figures
- ANAB's LTM Mar 2026 accounts receivables of $7.86M is the 2nd largest of the 10 companies compared; the peer median is $0.
- Its year-over-year change of +44.2% is the 4th highest of 8, against a peer median of +38.7%.
- Accounts receivables amounts to 3.4% of revenue for ANAB, versus a peer median of 7.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $8.54M | +12.9% | -8.0% | 8.1% | |
| LTM Mar 2026 | $7.86M | +44.2% | — | 3.4% | |
| LTM Mar 2026 | $6.81M | +5438.2% | +253.5% | 81.4% | |
| LTM Mar 2026 | $2.07M | +38.7% | +209.4% | — | |
| FY2025 | $776K | +198.4% | +512.8% | 1212.5% | |
| LTM Sep 2026 | $510K | +89.6% | — | 7.2% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $183K | -87.7% | — | — |
| LTM Jun 2026 | $67K | -104.1% | — | 3.5% | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ANAB) | $0 | +38.7% | +231.4% | 7.7% | |
Competitors are the stored peer set for ANAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (57.8M) | (128.72M) | (163.62M) | (145.23M) | 49.61M |
| Depreciation & Amortization | 2.09M | 2.34M | 2.38M | 2.4M | 2.42M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 15.35M | 27.36M | 33.21M | 34.05M | 36.07M |
| Change in Working Capital | (7.49M) | 6.84M | (324K) | (66.33M) | (80.73M) |
| Accounts Receivables | (876K) | (543K) | (5.43M) | (33.91M) | 6.92M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (4.74M) | 9.7M | 10.94M | (33.84M) | (87.33M) |
| Other Working Capital | (1.87M) | (2.32M) | (5.83M) | 1.43M | (313K) |
| Other Non-Cash Items | 1.93M | 18.6M | 7.56M | 39.77M | 12.31M |
| Operating Cash Flow | (45.92M) | (73.59M) | (120.8M) | (135.34M) | 19.7M |
| Capital Expenditures | (1.37M) | (358K) | (807K) | (358K) | (87K) |
| Acquisitions (Net) | 0 | 394.49M | 0 | 0 | 0 |
| Purchases of Investments | (118.66M) | (802.5M) | (303.92M) | (380.38M) | (196.41M) |
| Sales of Investments | 158.85M | 408.02M | 449.48M | 476.13M | 424.53M |
| Other Investing Activities | 15K | (394.49M) | 0 | 0 | 0 |
| Investing Cash Flow | 38.84M | (394.85M) | 144.75M | 95.4M | 228.03M |
| Debt Repayment | 0 | 0 | (11.73M) | 34.77M | (76.8M) |
| Common Stock Issued | 2.55M | 11.83M | 2.47M | 100.84M | 14.26M |
| Common Stock Repurchased | 0 | 0 | (50M) | (456K) | (68.63M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 249.75M | 32.19M | (43K) | (8.1M) | (1.45M) |
| Financing Cash Flow | 252.3M | 44.02M | (59.3M) | 127.05M | (132.61M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 245.21M | (424.42M) | (35.34M) | 87.12M | 115.12M |
| Free Cash Flow | (47.29M) | (73.95M) | (121.61M) | (135.7M) | 19.61M |
AnaptysBio, Inc.
NASDAQ:ANAB
Intrinsic Alpha fair value
Locked
Current Price
$47.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.